PDCD1 and non-small cell lung carcinoma: Other defined consortia (e.g., BMC128, MB097) and single-strain products (e.g., MRx0518) are being evaluated with PD-1 backbones across melanoma, NSCLC and RCC, to link colonization, metabolite flux, and immune remodeling to patient outcomes [269–272].